Key result
Treatment with ACE-inhibitors reduced the risk of all-cause mortality compared to placebo in patients at high vascular risk.
Why the study?
Do ACE-inhibitors reduce all-cause mortality in patients at high vascular risk?
Do ACE-inhibitors reduce all-cause mortality in patients at high vascular risk?
Answers are grounded in this paper and cite their sources.
ACE-inhibitors significantly reduce all-cause mortality in patients at high vascular risk, regardless of the presence of overt heart failure.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Gianpaolo Reboldi Cristina Poltronieri (2013) conducted an editorial in High vascular risk. ACE-Inhibitors vs. Placebo was evaluated on All-cause mortality (RR 0.87, 95% CI 0.83-0.91, p=<0.0001). Treatment with ACE-inhibitors reduced the risk of all-cause mortality compared to placebo in patients at high vascular risk.
Synapse has enriched 10 related papers. Consider them for comparative context: